Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TGTX |
---|---|---|
09:32 ET | 17929 | 18.5714 |
09:34 ET | 8828 | 18.57 |
09:36 ET | 24501 | 18.41 |
09:38 ET | 12138 | 18.43 |
09:39 ET | 9964 | 18.64 |
09:41 ET | 11594 | 18.72 |
09:43 ET | 12697 | 18.75 |
09:45 ET | 20513 | 18.79 |
09:48 ET | 14773 | 18.785 |
09:50 ET | 24138 | 18.8299 |
09:52 ET | 5344 | 18.79 |
09:54 ET | 11891 | 18.83 |
09:56 ET | 8518 | 18.7952 |
09:57 ET | 8851 | 18.79 |
09:59 ET | 5562 | 18.805 |
10:01 ET | 14386 | 18.845 |
10:03 ET | 4883 | 18.85 |
10:06 ET | 10242 | 18.865 |
10:08 ET | 2932 | 18.81 |
10:10 ET | 5843 | 18.88 |
10:12 ET | 13735 | 18.85 |
10:14 ET | 6066 | 18.91 |
10:15 ET | 3986 | 18.845 |
10:17 ET | 3044 | 18.85 |
10:19 ET | 8141 | 18.845 |
10:21 ET | 2649 | 18.87 |
10:24 ET | 1875 | 18.85 |
10:26 ET | 6853 | 18.825 |
10:28 ET | 600 | 18.825 |
10:30 ET | 4188 | 18.839 |
10:32 ET | 3544 | 18.8345 |
10:33 ET | 1700 | 18.84 |
10:35 ET | 2401 | 18.81 |
10:37 ET | 12646 | 18.75 |
10:39 ET | 6101 | 18.75 |
10:42 ET | 21694 | 18.69 |
10:44 ET | 1922 | 18.725 |
10:46 ET | 3094 | 18.72 |
10:48 ET | 2958 | 18.7 |
10:50 ET | 3402 | 18.72 |
10:51 ET | 710 | 18.74 |
10:53 ET | 2267 | 18.74 |
10:55 ET | 1200 | 18.75 |
10:57 ET | 2077 | 18.74 |
11:00 ET | 5076 | 18.71 |
11:02 ET | 18149 | 18.66 |
11:04 ET | 10033 | 18.68 |
11:06 ET | 6355 | 18.7 |
11:08 ET | 1700 | 18.68 |
11:09 ET | 3104 | 18.67 |
11:11 ET | 11244 | 18.57 |
11:13 ET | 9531 | 18.5842 |
11:15 ET | 3700 | 18.6 |
11:18 ET | 812 | 18.59 |
11:20 ET | 2893 | 18.59 |
11:22 ET | 1633 | 18.595 |
11:24 ET | 1028 | 18.595 |
11:26 ET | 4995 | 18.61 |
11:27 ET | 915 | 18.6 |
11:29 ET | 3147 | 18.665 |
11:31 ET | 4164 | 18.62 |
11:33 ET | 950 | 18.61 |
11:36 ET | 13347 | 18.6 |
11:38 ET | 5217 | 18.62 |
11:40 ET | 700 | 18.615 |
11:42 ET | 12881 | 18.59 |
11:44 ET | 4333 | 18.62 |
11:45 ET | 2358 | 18.65 |
11:47 ET | 6266 | 18.7 |
11:49 ET | 9587 | 18.67 |
11:51 ET | 3099 | 18.675 |
11:54 ET | 2065 | 18.655 |
11:56 ET | 3046 | 18.65 |
11:58 ET | 2096 | 18.63 |
12:00 ET | 1200 | 18.63 |
12:02 ET | 10047 | 18.62 |
12:03 ET | 5946 | 18.61 |
12:05 ET | 7769 | 18.61 |
12:07 ET | 5482 | 18.61 |
12:09 ET | 1983 | 18.6181 |
12:12 ET | 6308 | 18.63 |
12:14 ET | 1222 | 18.58 |
12:16 ET | 7004 | 18.6 |
12:18 ET | 603 | 18.6 |
12:20 ET | 10444 | 18.54 |
12:21 ET | 3936 | 18.575 |
12:23 ET | 2752 | 18.6 |
12:25 ET | 5655 | 18.6 |
12:27 ET | 1250 | 18.6 |
12:30 ET | 2571 | 18.58 |
12:32 ET | 4847 | 18.58 |
12:34 ET | 900 | 18.57 |
12:36 ET | 2107 | 18.59 |
12:38 ET | 5033 | 18.62 |
12:39 ET | 1050 | 18.6 |
12:41 ET | 5822 | 18.57 |
12:43 ET | 10754 | 18.57 |
12:45 ET | 1400 | 18.586 |
12:48 ET | 1277 | 18.585 |
12:50 ET | 6875 | 18.62 |
12:52 ET | 537 | 18.6282 |
12:54 ET | 4215 | 18.65 |
12:56 ET | 1323 | 18.66 |
12:57 ET | 3673 | 18.61 |
12:59 ET | 300 | 18.62 |
01:01 ET | 1243 | 18.64 |
01:03 ET | 500 | 18.62 |
01:06 ET | 1132 | 18.6 |
01:08 ET | 7572 | 18.61 |
01:10 ET | 900 | 18.59 |
01:12 ET | 2679 | 18.6 |
01:14 ET | 900 | 18.59 |
01:15 ET | 3366 | 18.5877 |
01:17 ET | 2270 | 18.57 |
01:19 ET | 4811 | 18.575 |
01:21 ET | 15610 | 18.61 |
01:24 ET | 3963 | 18.6 |
01:26 ET | 2700 | 18.61 |
01:28 ET | 1976 | 18.6 |
01:30 ET | 590 | 18.61 |
01:32 ET | 1485 | 18.61 |
01:33 ET | 3886 | 18.61 |
01:35 ET | 1300 | 18.61 |
01:37 ET | 2965 | 18.64 |
01:39 ET | 600 | 18.64 |
01:42 ET | 1956 | 18.65 |
01:44 ET | 8920 | 18.74 |
01:46 ET | 3026 | 18.745 |
01:48 ET | 3288 | 18.7 |
01:50 ET | 1850 | 18.69 |
01:51 ET | 8598 | 18.73 |
01:53 ET | 10046 | 18.74 |
01:55 ET | 2639 | 18.745 |
01:57 ET | 1256 | 18.725 |
02:00 ET | 400 | 18.72 |
02:02 ET | 2085 | 18.72 |
02:04 ET | 3220 | 18.69 |
02:06 ET | 500 | 18.69 |
02:08 ET | 5596 | 18.665 |
02:09 ET | 7358 | 18.67 |
02:11 ET | 1149 | 18.67 |
02:13 ET | 2270 | 18.65 |
02:15 ET | 7773 | 18.69 |
02:18 ET | 1802 | 18.71 |
02:20 ET | 849 | 18.7 |
02:22 ET | 600 | 18.7 |
02:24 ET | 3079 | 18.72 |
02:26 ET | 300 | 18.71 |
02:27 ET | 300 | 18.71 |
02:29 ET | 800 | 18.715 |
02:31 ET | 3903 | 18.765 |
02:33 ET | 3461 | 18.75 |
02:36 ET | 885 | 18.77 |
02:38 ET | 4400 | 18.77 |
02:40 ET | 7084 | 18.765 |
02:42 ET | 1900 | 18.74 |
02:44 ET | 1000 | 18.72 |
02:45 ET | 1792 | 18.715 |
02:47 ET | 1526 | 18.73 |
02:49 ET | 4197 | 18.74 |
02:51 ET | 5309 | 18.7301 |
02:54 ET | 3645 | 18.7461 |
02:56 ET | 1111 | 18.74 |
02:58 ET | 1141 | 18.735 |
03:00 ET | 2247 | 18.735 |
03:02 ET | 1549 | 18.745 |
03:03 ET | 1934 | 18.75 |
03:05 ET | 8926 | 18.8 |
03:07 ET | 7090 | 18.81 |
03:09 ET | 7747 | 18.755 |
03:12 ET | 1200 | 18.76 |
03:14 ET | 2327 | 18.79 |
03:16 ET | 6400 | 18.75 |
03:18 ET | 2550 | 18.725 |
03:20 ET | 1971 | 18.73 |
03:21 ET | 9576 | 18.71 |
03:23 ET | 3720 | 18.72 |
03:25 ET | 4045 | 18.73 |
03:27 ET | 8023 | 18.73 |
03:30 ET | 1200 | 18.73 |
03:32 ET | 13591 | 18.765 |
03:34 ET | 5259 | 18.77 |
03:36 ET | 4754 | 18.755 |
03:38 ET | 3298 | 18.775 |
03:39 ET | 9354 | 18.76 |
03:41 ET | 17319 | 18.8 |
03:43 ET | 4093 | 18.8 |
03:45 ET | 6162 | 18.815 |
03:48 ET | 7221 | 18.815 |
03:50 ET | 6499 | 18.83 |
03:52 ET | 23454 | 18.9 |
03:54 ET | 21776 | 18.955 |
03:56 ET | 42166 | 19.035 |
03:57 ET | 61013 | 18.965 |
03:59 ET | 79064 | 19.01 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
TG Therapeutics Inc | 2.9B | 86.2x | --- |
Twist Bioscience Corp | 2.8B | -14.5x | --- |
Arrowhead Pharmaceuticals Inc | 3.1B | -6.0x | --- |
MorphoSys AG | 2.8B | -5.5x | --- |
ADMA Biologics Inc | 2.6B | -561.8x | --- |
Denali Therapeutics Inc | 3.0B | -21.9x | --- |
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.9B |
---|---|
Revenue (TTM) | $289.3M |
Shares Outstanding | 154.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.23 |
EPS | $0.22 |
Book Value | $1.06 |
P/E Ratio | 86.2x |
Price/Sales (TTM) | 10.0 |
Price/Cash Flow (TTM) | 70.2x |
Operating Margin | 16.71% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.